However, we did not find a significant difference in tumor immune cell infiltration, the activities of tumor-infiltrating CD8+ and CD4+ T cells, or the number of tumor-infiltrating M1/M2 TAMs between the PS-α-PD-L1 group and the other treatment groups. This evidence concerns the gene CD274 and neoplasm.